Tonlamarsen

Studies of tonlamarsen measured 2 outcomes: office systolic blood pressure and blood pressure.

4 papers study it2 findingsUpdated Nov 2, 2026

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 1 trial, none about aging.

“the placebo-subtracted mean change in office SBP was -5.6 mmHg (95% CI, -8.6, -2.6, p<0.001)”

1 study gave tonlamarsen to people and measured what changed.

What changed	Design	People	Source
down: Decreases office systolic blood pressure-5.6 mmHg versus placebo; 95% CI -8.6 to -2.6; p<0.001	Trial4 weeks	204 peopleadultsHypertension on stable doses of 2-5 antihypertensives; intra-patient comparison with preceding placebo lead-in	AHA Scientific Sessions 2026 abstract, Nov 2, 2026

Studies of tonlamarsen measured 2 outcomes: office systolic blood pressure and blood pressure.

Office systolic blood pressure

downin humans1

1 study

Tonlamarsen decreases office systolic blood pressure in humans (-5.6 mmHg versus placebo; 95% CI -8.6 to -2.6; p<0.001).
“the placebo-subtracted mean change in office SBP was -5.6 mmHg (95% CI, -8.6, -2.6, p<0.001)”
Human trialHypertension on stable doses of 2-5 antihypertensives; intra-patient comparison with preceding placebo lead-inantisense oligonucleotidesingle dose4 weeksn = 204
Blood Pressure Lowering Following a Single Dose of Tonlamarsen Compared with a Single Dose of Placebo: A Post-Hoc Analysis of the KARDINAL Randomized Trial
AHA Scientific Sessions 2026 abstractNov 2, 2026

Blood pressure

downin humans1

1 study

Tonlamarsen decreases blood pressure in clinical trials.
“Recent translational advances, including RNA-based therapeutics such as small interfering RNAs (zilebesiran) and antisense oligonucleotides (tonlamarsen), demonstrate promising blood pressure reductions and favorable safety profiles in clinical trials.”
Reviewin clinical trials
Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research
Hypertension (Dallas, Tex. : 1979)Mar 19, 2026